March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
March 9th 2023
Data from a prospective pilot study indicate that circulating tumor DNA may be a valuable prognostic biomarker in early-stage follicular lymphoma.
March 1st 2023
Julia Dai, MD, and Madeleine Duvic, MD, present a comprehensive review of the current state of research and treatment in cutaneous T-cell lymphoma.
February 23rd 2023
A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.
February 20th 2023
The FDA states that the refusal to file letter for SGX301 in early-stage cutaneous T-cell lymphoma was because the new drug application was insufficient for permit substantive review.
2 Clarke Drive Cranbury, NJ 08512